myGenome

is the whole genome sequencing service and interpretation aimed to improve your patient's health

Veritas
INTERCONTINENTAL
The Genome Company


*"**The Genome** will soon replace all other genetic tests."*
George Church, Co-Founder, Veritas Genetics

my Genome by Veritas

myGenome is the most comprehensive preventive genetic test for healthy patients

myGenome is the genome sequencing and interpretation service intended to help prevent diseases and improve the health of your patients. The test provides key genetic information to the patient and his or her physician in order to adapt the individual's lifestyle and medical care. The test is intended for healthy individuals that want to be proactive in their healthcare.

myGenome INCLUDES:

- Whole GENOME sequencing from a saliva or blood sample obtained with a Veritas kit.
- Analysis of genes related to actionable diseases with clinical utility.
- Genetic information storage for future consultations.

myGenome has been developed by experts in genetics, bioinformatics and specialized physicians from the Harvard School of Medicine with more than 10 years of experience in the study and analysis of the human genome.

WHY SEQUENCE THE GENOME?

15-20%

Between 15-20%[1] of cancer cases are due to familial aggregation that increases the risk of cancer in the family.

3%

Around 3%[2] of the couples planning to have children have a 25% risk of having a child affected by a genetic disease.

15-20%

Between 15-20%[3] of sudden cardiac deaths are due to genetic variations in genes responsible for the structure of the cardiac muscle or the cardiac rhythm.

6%

Around 6%[4] of the population have an increased risk of developing hereditary thrombosis. Acquired factors such as bed rest or lack of physical activity increase the risk.

3-5%

Between 3-5%[5] of hospital admissions in Europe are due to adverse drug reactions.

WHAT TYPE OF DISEASES ARE INCLUDED?

- Diseases selected based on the American College of Medical Genetics and Genomics criteria that emphasizes the importance of analyzing cardiovascular diseases and risk of hereditary cancer, since they are the most frequent and actionable diseases.

- More than 650 diseases are reported in the following categories:



Advantages

Actionable Diseases

Diseases selected based on clinical guidelines by a group of experts with more than 10 years of experience in whole genome analysis and interpretation

Variant Curation

Team of geneticists dedicated to variant reanalysis that ensures that each variant classification is based on the most recent scientific knowledge enhancing the proprietary database

Detailed Report

Comprehensive report with detailed information that is easy to understand for the patient

Genetic Counseling

Differential service of expert genetic counseling in several medical areas. Support to specialists and patients

Information Updates

Classification update of clinically significant variants. Veritas offers access to information of interest that can be incorporated in the future

Clinical Examples

RESULT	CLINICAL IMPLICATION	PREVENTIVE ACTION
Pathogenic variant in *MYBPC3* gene	**Risk of hypertrophic cardiomyopathy** Heart defect associated with sudden cardiac death	Consider consulting a cardiologist for counseling and follow-up
Pathogenic variant in *ATM* gene	**Breast cancer risk** Women have 2-4 times greater risk of breast cancer and other cancers such as pancreatic	Establish a specific gynecological screening plan and personalized follow-up with a physician
Pathogenic variant in *RYR1* gene	**Risk of malignant hyperthermia** Hypermetabolic reaction to muscle relaxants commonly used in surgery, causing stiffness, tachycardia, fever and muscle breakdown	When surgery is required, notify the anesthesiologist to change the pharmacological prescription accordingly
Pathogenic variant in *F5* gene	**Risk of venous thrombosis** 5% risk of deep vein thrombosis	Inform the specialist in case of surgery, prolonged rest, pregnancy, etc.


myGenome is a key complement for
patient health checkups

Report Sections



1 Clinical results

Interpretation of 566 genes selected based on the American College of Medical Genetics and Genomics criteria, related to conditions that have an important impact on the patient's health. Full gene analysis is performed reporting pathogenic and likely pathogenic variants. This information is key to personalize medical management.

2 Carrier status

Analysis of over 200 diseases where the patient can be an asymptomatic carrier. If both members of the couple are carriers of the same disease, they have a higher risk of transmitting it to their children.*

3 Multifactorial diseases

Analysis of specific variants related to multifactorial conditions where both genetic and environmental risk factors are involved. This information allows the adaptation of patient's lifestyle based on genetics.

4 Pharmacogenomics

myGenome analyzes genes related to metabolism, secondary drug targets and transporters in order to know the effect of more than 150 pharmaceuticals on the patient, which allows a personalized prescription. The drugs analyzed are included in the following medical areas:

- Cardiovascular
- Hematology
- Infectious diseases and immune disorders
- Oncology
- Transplantation Medicine
- Pain Medicine
- Gastroenterology
- Neurology

**myGenome should not replace a clinical screening test for carriers*

5 Traits

Veritas also includes the analysis of traits that do not have a clinical impact on the patient's health, but allow to make informed decisions based on genetics. The following traits are analyzed:

Athleticism

- Achilles Tendinopathy
- Exercise Response
- Ligament Injury Susceptibility
- Lumbar Disc Disease
- Susceptibility
- Muscle Strength
- Muscle Volume
- Muscular Endurance
- Muscular Power

Longevity

- Longevity

Metabolism

- Metabolic Syndrome
- Resting Metabolic Rate
- Weight Gain
- Obesity

Immune system

- IL-6 Levels

Cardiovascular

- Blood Pressure
- Baseline Cholesterol

Nutrition and Diet

- Polyunsaturated Fats
- Vitamin B12
- Vitamin B6
- Vitamin C
- Vitamin D
- Vitamin E

Hormones

- IGF-1 Levels
- Menopause Age
- Testosterone Levels

Physical appearance

- Earwax Type
- Eye Color
- Finger Length Ratio
- Freckling
- Hair Color
- Hair Curl
- Hair Thickness
- Height
- Iris Patterns
- Male Pattern Baldness
- Pigmentation

Behavior

- Hunger Response Control
- Snacking Behavior
- Sugar Intake
- Sweet Tooth

Substance reaction

- Alcohol Sensitivity
- Coffee and Caffeine
- Nicotine Response

Sensory perception

- Asparagus Metabolite Odor Detection in Urine
- Bitter Taste Perception
- Cilantro (Coriander) Preference
- Misophonia (Sensitivity to Chewing Sounds)
- Nearsightedness (Myopia)
- Odor Detection
- Pain Sensitivity
- Photic Sneeze Reflex
- Sweetness Detection

6 Ancestry

myGenome analyzes variants in the DNA to establish the ancestral origin of the patient based on genetics.

Genes with clinical interpretation

ABCC8	*ATP7B*	*CDH1*	*CYP11B1*	*ERCC1*	*FKBP14*	*HFE*	*LIPA*	*MYCN*	*PAX5*	*PSEN2*	*RPS28*	*SLMAP*	*TP53*
ABCC9	*ATR*	*CDK4*	*CYP11B2*	*ERCC2*	*FKRP*	*HIP1*	*LITAF*	*MYH11*	*PC*	*PTCH1*	*RPS29*	*SLX4*	*TPM1*
ABCD1	*AURKA*	*CDKN1B*	*CYP19A1*	*ERCC3*	*FKTN*	*HLCS*	*LMF1*	*MYH6*	*PCDH15*	*PTCH2*	*RPS7*	*SMAD3*	*TPP1*
ABCG5	*AXIN2*	*CDKN1C*	*CYP1B1*	*ERCC4*	*FLCN*	*HMBS*	*LMNA*	*MYH7*	*PCSK9*	*PTEN*	*RTEL1*	*SMAD4*	*TRDN*
ABCG8	*B3GALT6*	*CDKN2A*	*CYP21A2*	*ERCC5*	*FXN*	*HMMR*	*LPL*	*MYL2*	*PDCD10*	*PTPN11*	*RUNX1*	*SMARCA4*	*TRIM37*
ABRAXAS1	*B4GALT7*	*CEBPA*	*CYP27A1*	*ERCC6*	*G6PC*	*HNF1A*	*LRPPRC*	*MYL3*	*PDGFRA*	*PYGM*	*RYR1*	*SMARCB1*	*TRIM63*
ACADM	*BAG3*	*CEBPE*	*DCLRE1C*	*ESR1*	*G6PC3*	*HOXB13*	*LSP1*	*MYLK*	*PDLIM3*	*RAD50*	*RYR2*	*SMARCE1*	*TRMU*
ACADSB	*BAP1*	*CEP57*	*DDB2*	*ETFDH*	*G6PD*	*HPS1*	*LTBP2*	*MYLK2*	*PEX12*	*RAD51*	*SACS*	*SMPD1*	*TRPM4*
ACADVL	*BARD1*	*CERKL*	*DDR2*	*ETV6*	*GAA*	*HRAS*	*LZTR1*	*MYO6*	*PEX6*	*RAD51B*	*SALL4*	*SNTA1*	*TSC1*
ACD	*BBS1*	*CETP*	*DDX41*	*EVC*	*GALC*	*HSPB8*	*MAP2K1*	*MYO7A*	*PHB*	*RAD51C*	*SBDS*	*SOS1*	*TSC2*
ACSF3	*BBS2*	*CFTR*	*DES*	*EXO1*	*GALK1*	*HYLS1*	*MAP2K2*	*MYOM1*	*PHOX2B*	*RAD51D*	*SCN1B*	*SPG11*	*TSFM*
ACTA1	*BCHE*	*CHEK2*	*DHCR7*	*EXT1*	*GALNT12*	*IKZF1*	*MAP3K1*	*MYOZ2*	*PICALM*	*RAD54L*	*SCN2B*	*SPINK1*	*TSHR*
ACTA2	*BCKDHA*	*CHRM2*	*DICER1*	*EXT2*	*GALT*	*ILK*	*MAX*	*MYPN*	*PIK3CA*	*RAF1*	*SCN3B*	*SREBF2*	*TTN*
ACTC1	*BCKDHB*	*CHRNE*	*DIS3L2*	*EYA4*	*GATA1*	*ITK*	*MC1R*	*NBN*	*PKD2*	*RANGRF*	*SCN4B*	*SRGAP1*	*TTR*
ACTN2	*BLM*	*CHST14*	*DKC1*	*EYS*	*GATA2*	*IVD*	*MCOLN1*	*NDRG1*	*PKHD1*	*RB1*	*SCN5A*	*STAT3*	*TXNRD2*
ACVRL1	*BMPR1A*	*CLN5*	*DMD*	*EZH2*	*GATAD1*	*JAG1*	*MED17*	*NDUFS6*	*PKP2*	*RBBP8*	*SCO2*	*STK11*	*TYR*
ADAMTS2	*BRAF*	*CLRN1*	*DNAJC19*	*F11*	*GBA*	*JAK2*	*MEFV*	*NEBL*	*PLA2G2A*	*RBM15*	*SDHA*	*SUFU*	*UROD*
AGA	*BRCA1*	*CNGB3*	*DOCK8*	*F5*	*GBE1*	*JPH2*	*MEN1*	*NEFL*	*PLN*	*RBM20*	*SDHAF2*	*TAZ*	*USB1*
AGL	*BRCA2*	*COL1A1*	*DOLK*	*F8*	*GCDH*	*JUP*	*MESP2*	*NEXN*	*PLOD1*	*RECQL*	*SDHB*	*TBX20*	*USH2A*
AIP	*BRIP1*	*COL1A2*	*DPP6*	*F9*	*GCKR*	*KCNA5*	*MET*	*NF1*	*PMM2*	*RECQL4*	*SDHC*	*TBX3*	*VCL*
AIRE	*BTD*	*COL3A1*	*DPYD*	*FAH*	*GDF2*	*KCND3*	*MGMT*	*NF2*	*PMP22*	*RET*	*SDHD*	*TBX5*	*VHL*
AKAP9	*BUB1B*	*COL5A1*	*DSC2*	*FAM161A*	*GEN1*	*KCNE1*	*MIB1*	*NHP2*	*PMS1*	*RHBDF2*	*SEC23B*	*TCAP*	*WAS*
AKT1	*CACNA1C*	*COL5A2*	*DSE*	*FAN1*	*GJA5*	*KCNE2*	*MITF*	*NKX2-5*	*PMS2*	*RINT1*	*SELENON*	*TCIRG1*	*WRAP53*
ALDOB	*CACNA1S*	*COL7A1*	*DSG2*	*FANCA*	*GJB2*	*KCNE3*	*MKS1*	*NODAL*	*POLD1*	*RIT1*	*SEPSECS*	*TECPR2*	*WRN*
ALK	*CACNA2D1*	*COX15*	*DSP*	*FANCB*	*GJB6*	*KCNE5*	*MLC1*	*NOP10*	*POLE*	*RMRP*	*SERPINA1*	*TERC*	*WT1*
ALMS1	*CACNB2*	*CPT1A*	*DTNA*	*FANCC*	*GLA*	*KCNH2*	*MLH1*	*NOTCH1*	*POLG*	*ROBO2*	*SGCB*	*TERT*	*XPA*
ALPL	*CALM1*	*CPT2*	*DYSF*	*FANCD2*	*GLB1*	*KCNJ2*	*MLH3*	*NOTCH3*	*POLH*	*ROS1*	*SGCD*	*TGFB2*	*XPC*
ANK2	*CALM2*	*CREB3L3*	*EFEMP2*	*FANCE*	*GLE1*	*KCNJ5*	*MPL*	*NPHS1*	*POT1*	*RPE65*	*SGCG*	*TGFB3*	*XRCC2*
ANKRD1	*CALR3*	*CREBBP*	*EGFR*	*FANCF*	*GNE*	*KCNJ8*	*MPV17*	*NPPA*	*PPM1D*	*RPL11*	*SH2D1A*	*TGFBR1*	*XRCC3*
APC	*CASP8*	*CRELD1*	*EGLN1*	*FANCG*	*GPC3*	*KCNQ1*	*MPZ*	*NQO2*	*PPT1*	*RPL15*	*SHOC2*	*TGFBR2*	*ZBTB17*
APOA4	*CASQ2*	*CRYAB*	*EGLN2*	*FANCI*	*GPD1L*	*KIF1B*	*MRE11*	*NRAS*	*PRDM16*	*RPL26*	*SLC12A3*	*TINF2*	*ZHX3*
APOA5	*CASR*	*CSRP3*	*EGR2*	*FANCL*	*GPIHBP1*	*KIT*	*MSH2*	*NSD1*	*PRDM5*	*RPL27*	*SLC12A6*	*TLR2*	*ZIC3*
APOB	*CAV3*	*CTC1*	*ELANE*	*FANCM*	*GREM1*	*KLF10*	*MSH3*	*NTHL1*	*PRF1*	*RPL31*	*SLC17A5*	*TMEM127*	*ZNF469*
APOC2	*CAVIN4*	*CTF1*	*ELN*	*FAS*	*H19*	*KLLN*	*MSH6*	*ODC1*	*PRKAG2*	*RPL35A*	*SLC22A5*	*TMEM43*	
APOE	*CBL*	*CTLA4*	*ELP1*	*FAT1*	*HABP2*	*KRAS*	*MSR1*	*OPA3*	*PRKAR1A*	*RPL5*	*SLC25A13*	*TMPO*	
AR	*CBS*	*CTNNA1*	*EMD*	*FBN1*	*HADHA*	*LAMA2*	*MTAP*	*OPCML*	*PRKDC*	*RPS10*	*SLC25A15*	*TNNC1*	
ARID5B	*CBX8*	*CTNNB1*	*ENG*	*FBN2*	*HAX1*	*LAMA4*	*MTHFR*	*OTC*	*PRKG1*	*RPS19*	*SLC25A4*	*TNNI3*	
ARSA	*CCM2*	*CTNS*	*EP300*	*FGFR2*	*HBB*	*LAMP2*	*MUT*	*PAH*	*PRKN*	*RPS20*	*SLC26A2*	*TNNT2*	
ASNS	*CCND1*	*CTRC*	*EPAS1*	*FH*	*HCN4*	*LDB3*	*MUTYH*	*PALB2*	*PRNP*	*RPS24*	*SLC26A4*	*TNXB*	
ASPA	*CD82*	*CYBA*	*EPCAM*	*FHL1*	*HEXA*	*LDLR*	*MXI1*	*PALLD*	*PRSS1*	*RPS26*	*SLC2A10*	*TOR1A*	
ATM	*CDC73*	*CYLD*	*ERBB2*	*FHL2*	*HEXB*	*LDLRAP1*	*MYBPC3*	*PARN*	*PSEN1*	*RPS27*	*SLC39A13*	*TOX3*	

my Genome

+650	Diseases of hereditary origin
+225	Conditions that you may pass on to your children
15	Multifactorial conditions, included in the “Risks” section of the report
+150	Information about drug sensitivities
+50	Information on genetic traits related to diet, athletics, longevity, nutrition, behavior, cardiovascular health, metabolism and immune system
	Comprehensive Genetic Counseling pre and post test
	Information about your ancestors

myGenome *changes the concept of prevention, incorporating genetics as a tool for preventive medicine.*

Technical Information

» Whole genome sequencing with an average depth of 30x (gold standard for genome sequencing).
» Analytic sensitivity is 99% for SNVs* and 97.6% for small insertions/deletions (6 bases).
» Analysis and variant classification based on internal and external databases (ClinVar and HGMD**).
» Variant curation performed by our dedicated expert team with proprietary software developed for detailed variant classification.
» myGenome has been developed by a medical expert team with more than 10 years of experience in Whole Genome Sequencing, including members of the Personal Genome Project from the Harvard Medical School.

**Single Nucleotide Variants / **Human Gene Mutation Database*

References

1. https://seom.org/informacion-sobre-el-cancer/consejo-genetico.
2. Rotem BS et al. A Data-Driven Evaluation of the Size and Content of Expanded Carrier Screening Panels. Genetics in Medicine.doi:10.1038/s41436-019-0466-5
3. Orland KM et al. Molecular Autopsy for Sudden Cardiac Death: Current State and Considerations. Current Genetic Medicine Reports. 2019. https://doi.org/10.1007/s40142-019-00170-x
4. MacCallum P, et al. Diagnosis and management of heritable thrombophilias. BMJ 2014;349:g4387.
5. Bouvy JC et al. Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies. Drug Saf 2015;38:437–453

» Bagnall RD et al. A Prospective Study of Sudden Cardiac Death among Children and Young Adults. N Engl J Med 2016;374;25.
» Mellor G et al. Genetic Testing in the Evaluation of Unexplained Cardiac Arrest. Circ Cardiovasc Genet. 2017;10:e001686.
» Mandelker D et al. Navigating highly homologous genes in a molecular diagnostic setting: a resource for clinical next-generation sequencing. Genet Med 2016;18:1282-1289.
» Landrum MJ et al. ClinVar: public archive of interpretations of clinically relevant variants. Nuc Acids Res 2016;44(1):D862–D868. doi: 10.1093/nar/gkv1222. PMID 26582918.
» Zook JM. et al. Extensive sequencing of seven human genomes to characterize benchmark reference materials. Sci Data 2016;3:160025 doi: 10.1038/sdata.2016.25.
» Richards S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-424. PMID 25741868.
» Stenson PD et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet 2017;136:665-677.
» Whirl-Carrillo M. et al. Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2012; 92:414-417. PMID 22992668.
» S. Kalia et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017 Feb;19(2):249-255. doi: 10.1038/gim.2016.190. Epub 2016 Nov 17.
» M. Lindor et al. Whole-Genome sequencing in healthy people. Mayo Clin Proc. January 2017;92(1):159-172 http://dx.doi.org/10.1016/j.mayocp.2016.10.019.

Veritas is *The Genome Company*. Our mission is to deliver on the promise of the human genome, empowering people to maximize quality and length of life for themselves and their families.

As the first company to introduce **WHOLE GENOME SEQUENCING** and its interpretation to consumers and their physicians, we lead by relentlessly pushing the boundaries of science and technology while driving down the cost of the genome.

Founded in 2014 by leaders in genomics from Harvard Medical School, Veritas has been recognized by MIT Technology Review as one of the 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the world's most innovative health companies in 2018, and by CNBC as one of the Disruptor 50 Companies in 2018 and 2019.

Veritas Intercontinental was founded in 2018 to lead the expansion of the Veritas' brand and genetic services in Europe, Latin America, the Middle East, and Japan.

SKY LAB

DIAGNOSTIC CENTER

info@skymedical.us

skymedical.us

MB.MG_EN_V1.0
26/04/21